PN is a chronic neuroimmune skin condition1

A cycle of itching and scratching leading to further skin damage1

PN is defined by a relentless itch and the presence of hard, itchy nodules that form on the skin's surface, primarily affecting the arms, legs, and trunk.1

  • PN has the highest itch intensity among the many types of chronic pruritus1
  • This itch can be associated with multiple sensations, such as stinging, prickling, burning, and pain2

The intense itch of PN is the most burdensome symptom for patients3

 

reported itch as their top 
complaint to their doctor3

 

rated itch as their 
worst symptom4

 

reported itch as a direct 
cause of sleep disturbance4

What is driving the itch and scratching of PN?

Complex neuroimmune interactions contribute to the pathophysiology of PN1,5

Neuronal mechanisms

Itch signals transmitted to the central nervous system from the skin are enhanced by elongation and branching of sensory neurons1,5

IMMUNE mechanisms

Cytokines released by immmune cells and impaired keratinocyte differentiation amplify itch1,5

The role of IL-31 in itch and more5-11

Unlike other cytokines, IL-31 has emerged as a key neuroimmune cytokine and a direct driver of:

  • ITCH
  • INFLAMMATION
  • skin barrier DYSFUNCTION
  • FIBROSIS

Fast Itch Relief

See how NEMLUVIO significantly improved itch in both pivotal and long-term studies12

VIEW THE DATA 

Unique Mechanism of Action

NEMLUVIO is the first treatment to target IL‑31RA, a key neuroimmune driver of itch and more to disrupt PN11,13

SEE HOW 

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Please see full Prescribing Information, including Patient Information.